☆ 4.4 Article

Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia

HEMATOLOGICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia

Chaitra Ujjani et al.

Summary: This study found that SARS-CoV-2 vaccine efficacy was lower in chronic lymphocytic leukemia (CLL) patients, with decreased rates of seroconversion and lower antibody levels compared to healthy controls. The results from the Roche anti-S assay and neutralization activity were similar. Durable immune responses were observed up to six months, and booster shots were effective in improving the immune response in patients who had a response. The absence of normal B cells, commonly seen in CLL patients receiving certain treatments, was a strong predictor of lack of seroconversion.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Hematology

Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia

Marta Morawska

Summary: Patients with chronic lymphocytic leukemia have limited response to COVID-19 vaccination, with less than half developing antibody response, leaving them at risk of infection. Factors contributing to inadequate response include disease-related immune dysregulation, patient-related factors, and therapy-related factors.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia

Zoe L. Lyski et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Letter Hematology

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

J. Erika Haydu et al.

Summary: This prospective study demonstrates that SARS-CoV-2 vaccination induces functional T-cell and antibody responses in patients with CLL. The serologic response to the vaccine is more common in treatment-naive patients. Most patients had functional spike-specific T-cell responses in interferon-gamma release assays.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Oncology

Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia

Stefano Molica et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a lower immune response to COVID-19 vaccines compared to the general population. Including these patients in vaccine trials may improve their response. Additionally, the timing and frequency of vaccine boosters or re-vaccinations should be addressed, especially for patients on immunosuppressive therapies. Patients who do not have an antibody response may benefit from preventive antibody therapy.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Letter Hematology

SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia

Sibylle C. Mellinghoff et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer et al.

Summary: Treatment with BTK inhibitors resulted in a lower immune response rate to the HepB-CpG vaccine, but did not significantly affect the response rate to the RZV vaccine in CLL patients.

BLOOD (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Article Oncology

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

Maria Cristina Puzzolo et al.

Summary: Research suggests that ibrutinib treatment can reverse T-cell polarization in chronic lymphocytic leukemia (CLL), decreasing Th2 cells and increasing Th1 cells, with a gradual reduction in the Th2/Th1 ratio after treatment initiation. Furthermore, patients with a Th2/Th1 ratio below 0.088 at M8 are more likely to achieve complete remission (CR).

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jerome Hadjadj et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Letter Hematology

Ibrutinib may impair serological responses to influenza vaccination

Abby P. Douglas et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Letter Hematology

Ibrutinib may impair serological responses to influenza vaccination

Abby P. Douglas et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Review Immunology

Tumor-induced host immunosuppression: Special focus on CLL

Christine E. Cutucache

INTERNATIONAL IMMUNOPHARMACOLOGY (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.